Antimicrobial drug resistance and infection prevention/control: lessons from tuberculosis

  • J. Peter Cegielski JP Cegielski Consulting, LLC, Atlanta, GA, USA
  • Carrie Tudor International Council of Nurses, Geneva, Switzerland; and End TB Transmission Initiative, Stop TB Partnership, Geneva, Switzerland
  • Grigory V. Volchenkov End TB Transmission Initiative, Stop TB Partnership, Geneva, Switzerland; and Vladimir Regional TB Control Center, Vladimir, Russian Federation
  • Paul A. Jensen End TB Transmission Initiative, Stop TB Partnership, Geneva, Switzerland; and Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
Keywords: antimicrobial resistance, infection control, tuberculosis, surveillance, healthcare associated infections, healthcare workers


Antimicrobial drug resistance (AMR) is increasing rapidly worldwide, causing an estimated 700,000 deaths annually over the past decade, en route to becoming the leading global threat to public health by 2050 with an estimated 10 million deaths per year (more than heart disease, cancer, and stroke), while reducing global wealth by US$100 trillion. Yet AMR has not received the attention and action required to change this trajectory. Appropriate infection prevention and control (IPC) measures are needed to prevent transmission of infections to healthcare workers (HCWs), other patients, families, and the general public. In this review, we discuss a notable case study of AMR: highly drug-resistant tuberculosis (TB) has emerged repeatedly over the past 70 years as new drugs have been introduced, leading to new diagnostics, therapeutics, funding, public health strategies, and, in high-income countries, effective IPC measures that curtailed transmission. We review current efforts to control and prevent AMR using the example of drug-resistant tuberculosis to highlight important themes including laboratory systems, surveillance, control and prevention of healthcare-associated infections (especially among HCWs), better coordination across disciplines and diseases, and powerful advocacy/social change initiatives grounded in social and behavioral sciences. These strategies are the foundation of an effective response to the AMR threat to public health.


Download data is not yet available.


Ventola CL. The antibiotic resistance crisis, part 1: causes and threats. P T 2015; 40(4): 277–83.

World Health Organization. Global action plan on antimicrobial resistance. Geneva: WHO; 2015. WHA68/2015/REC/1, Annex 3.

World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva: WHO; 2014.

World Health Organization. Report on the burden of endemic health care-associated infection worldwide a systematic review of the literature. Geneva: WHO; 2014.

Interagency Coordination Group on Antimicrobial Resistance (IACG). No time to wait: securing the future from drug-resistant infections. Report To The Secretary-General Of The United Nations. April 2019. Available from: [cited 2 May 2019].

European Centre for Disease Prevention and Control, European Medicines Agency. ECDC/EMEA JOINT TECHNICAL REPORT The bacterial challenge: time to react. Stockholm: European Centre for Disease Prevention and Control, September; 2009. EMEA doc. ref. EMEA/576176/2009, ISBN 978-92-9193-193-4. doi: 10.2900/2518

World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020. License: CCBY-NC-SA 3.0 IGO.

O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. The review on antimicrobial resistance. December 2014.

Ventola CL. The antibiotic resistance crisis, part 2: management strategies and new agents. P T 2015; 40(5): 344–52.

World Health Organization. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. Geneva: World Health Organization; 2017. WHO/EMP/IAU/2017.12. Licence: CC BY-NC-SA 3.0 IGO.

Food and Agriculture Organization / World Organization for Animal Health / World Health Organization. Global framework for development & stewardship to combat antimicrobial resistance: draft roadmap. Geneva: United Nations; 2017. WHO/EMP/IAU/2017.08 (revised 19 October 2017).

Sciarretta K, Røttingen JA, Opalska A, Van Hengel AJ, Larsen J. Economic incentives for antibacterial drug development: literature review and considerations from the transatlantic task force on antimicrobial resistance. Clin Infect Dis 2016; 63(11): 1470–4. doi: 10.1093/cid/ciw593

The antibiotics industry is broken – but there’s a fix: attempts to develop new antibiotics are failing because the projects aren’t profitable. Maryn McKenna, – 4/27/2019, 7:30 AM.

Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol 2010; 1(134): 1–7. doi: 10.3389/fmicb.2010.00134

Theuretzbacher U, Gottwalt S, Beyer P, Butler M, Czaplewski L, Lienhardt C, et al. Analysis of the clinical antibacterial and antituberculosis pipeline. Lancet Infect Dis 2019(Feb); 19: e40–50. doi: 10.1016/S1473-3099(18)30513-9

Pearson ML, Jereb JA, Frieden TR, Crawford JT, Davis BJ, Dooley SW, et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis: a risk to patients and health care workers. Ann Intern Med 1992; 117: 191–6. doi: 10.7326/0003-4819-117-3-191

Rogers PD, Krysan DJ. Ch. 61: Antifungal agents. In: Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman’s the pharmacologic basis of therapeutics – 13 ed. New York: McGraw-Hill; 2018, pp. 1087–104.

Richtel M, Jacobs A. Fungus immune to drugs quietly sweeps the globe. The New York Times, Vol. CLXVII, No. 58,290. Sunday, April 7, 2019, p. 1.

Vinetz JM. Ch. 53: Chemotherapy of malaria. In: Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman’s the pharmacologic basis of therapeutics – 13 ed. New York: McGraw-Hill; 2018, pp. 969–86.

Fairhurst RM, Wellems TE. Malaria (Plasmodim species). ch. 276. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases–8th ed. Elsevier: Philadelphia, 2015, pp. 3070–3090.”

Beyrer C, Pozniak A. HIV drug resistance – an emerging threat to epidemic control. N Engl J Med 2017 Oct 26; 377(17): 1605–7. doi: 10.1056/NEJMp1710608

King DH. History, pharmacokinetics, and pharmacology of acyclovir. J Am Acad Dermatol 1988; 18(1)(part 2): 176–9. doi: 10.1016/S0190-9622(88)70022-5

World Health Organization. Update on oseltamivir resistance to influenza H1N1 (2009) viruses. December 15, 2010. Archived (PDF) from the original on January 30, 2011. [cited 30 December 2010].

Centers for Disease Control and Prevention. Antiviral drug resistance among influenza viruses guidance on the use of influenza antiviral agents (Current for the 2013–14 Influenza Season). CDC. Archived from the original on 13 February 2014. [cited 21 April 2014].

Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657–68. doi: 10.1086/499819

Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics. Clin Infect Dis 2013; 56(10): 1445–50. doi: 10.1093/cid/cit070

Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al. for the IDSA. The epidemic of antibiotic resistant infections: a call to action for the medical community from the IDSA. Clin Infect Dis 2008; 46: 155–64. doi: 10.1086/524891

Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martin-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13(3): 380–7. doi: 10.3201/eid1303.061400

Spellberg B, Gilbert DN. The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett. Clin Infect Dis 2014; 59(S2): S71–5. doi: 10.1093/cid/ciu392

2009 E.U.-U.S. Summit Declaration, p. 3, 3 Nov 2009.

O’Neill, et al. Tackling a global health crisis: initial steps. The Review on Antimicrobial Resistance. World Bank; 2015. Available from: [cited 30 June 2021].

O’Neill, et al. Tackling drug-resistant infections globally: final report and recommendations: the review on antimicrobial resistance. World Bank; 2016. Available from: [cited 30 June 2021].

Taylor J, Hafner M, Yerushalmi E, Smith R, Bellasio J, Vardavas R, et al. Estimating the economic costs of antimicrobial resistance: model and results. Santa Monica, CA: RAND Corporation; 2014.

Interagency Coordination Group on AMR (IACG). AMR framework for action supported by the IACG Working Document, August 2017.

IACG. Meeting the challenge of antimicrobial resistance: from communication to collective action. IACG Discussion Paper July 2018.

IACG. Reduce unintentional exposure and the need for antimicrobials, and optimize their use. IACG Discussion Paper July 2018.

WHO. Available from: [cited 6 June 2021].

Stop TB Partnership. Available from: [cited 14 September 2019].

Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs – worldwide, 2000–2004. MMWR 2006; 55(11): 301–5.

Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One 2013; 8(1): e54587. doi: 10.1371/journal.pone.0054587

The Economist Intelligence Unit. Time to end drug-resistant tuberculosis: a call to action. The Economist. London: The Economist Intelligence Unit, Ltd; 2019, pp. 1–36.

Shah NS, Auld SC, Brust JC, Mathema B, Ismail N, Moodley P, et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med 2017 Jan 19; 376(3): 243–53. doi: 10.1056/NEJMoa1604544

Wollenberg KR, Desjardins CA, Zalutskaya A, Slodovnikova V, Oler AJ, Quiñones M, et al. Whole genome sequencing of Mycobacterium tuberculosis provides insight into the evolution and genetic composition of drug-resistant tuberculosis in Belarus. J Clin Microbiol 2017 Feb; 55(2): 457–69. doi: 10.1128/JCM.02116-16

Gelmanova IY, Keshavjee S, Golubchikova VT, Berezina VI, Strelis AK, Yanova GV, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 2007 Sep; 85(9): 703–11. doi: 10.2471/BLT.06.038331

World Health Organization Global Tuberculosis Programme. TB: a global emergency, WHO report on the TB epidemic. Geneva: World Health Organization; 1994.

Beck-Sagué C, Dooley SW, Hutton MD, Otten J, Breeden A, Crawford JT, et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA 1992 Sep 9; 268(10): 1280–6. doi: 10.1001/jama.268.10.1280

The Lancet Editors. XDR-TB – a global threat. Lancet 2006(Sep16); 368(9540): 964. doi: 10.1016/S0140-6736(06)69391-4

Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006 Nov 4; 368(9547): 1575–80. doi: 10.1016/S0140-6736(06)69573-1

World Health Organization, Stop TB Partnership. The global MDR-TB and XDR-TB response plan 2007–2008. Geneva: World Health Organization; 2007. WHO reference number: WHO/HTM/TB/2007.387.

World Health Organization. Report of WHO global task force on XDR-TB emergency meeting in Geneva, Switzerland, 9–10 October 2006. Geneva: World Health Organization; 2007. WHO reference number: WHO/HTM/TB/2007.375. Available from: [cited 30 June 2020].

World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. Geneva: World Health Organization; 2008. ISBN: 978 92 4 154758 1. WHO reference number: WHO/HTM/TB/2008.402.

Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012 Feb 15; 54(4): 579–81. doi: 10.1093/cid/cir889

Gupta R, Cegielski P, Espinal MA, Henkens M, Kim JY, Lambregts-van Weezenbeek CSB, et al. Increasing transparency in partnerships for health: introducing the Green Light Committee. Trop Med Internat Health 2002; 7: 970–6. doi: 10.1046/j.1365-3156.2002.00960.x

Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blondal K, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006; 12: 1389–97. doi: 10.3201/eid1209.051618

W.H.O. Countries provide successful model for massive tuberculosis treatment scale-up. Available from: [cited 30 June 2019].

Green Light Committee Initiative of the Working Group on Multidrug-resistant Tuberculosis Annual report 2009. WHO reference number: WHO/HTM/TB/2010.14. Available from: [cited 30 June 2019].

Rich ML, Cegielski P, Jaramillo E, Lambregts-van Weezenbeek C (Eds-in-Chief). Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2006. WHO/HTM/TB/2006.36.

Kurbatova EV, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, et al. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16(10): 1–9. doi: 10.5588/ijtld.11.0811

Dalton T, Cegielski JP, Akksilp S, Ascencios L, Campos-Caoili J, Cho SN, et al. Prevalence of and risk factors for second-line drug resistance among adults with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380(9851): 1406–17. doi: 10.1016/S0140-6736(12)60734-X

Yuen CM, Kurbatova EV, Tupasi TE, Caoili JC, van der Walt M, Kvasnovsky C, et al. Association between regimen composition and treatment response in patients with multidrug-resistant tuberculosis: a prospective cohort study. PLoS Med 2015; 12(12): e1001932. doi: 10.1371/journal.pmed.1001932

Smith S, Ershova J, Vlasova N, Nikishova E, Tarasova I, Eliseev P, et al. Risk factors for acquired anti-tuberculosis drug resistance during multidrug-resistant tuberculosis treatment in Arkhangelsk Oblast, Russia. Emerg Infect Dis 2015 Jun; 21(6): 1002–11. doi: 10.3201/eid2106.141907

Cegielski JP, Dalton T, Yagui M, Wattanaamornket W, Volchenkov GV, Via LE, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014; 59 (8): 1049–63. doi: 10.1093/cid/ciu572

Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012 Jun 7; 366(23): 2151–60. doi: 10.1056/NEJMoa1112433

Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014 Aug 21; 371(8): 723–32. doi: 10.1056/NEJMoa1313865

Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A trial of a shorter regimen for Rifampin-resistant tuberculosis. N Engl J Med 2019; 380: 1201–13. doi: 10.1056/NEJMoa1811867

World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system: Policy statement. 15 February 2011. ISBN: 978 92 4 150154 5. WHO reference number: WHO/HTM/TB/2011.4.

World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis Interim policy guidance. 16 February 2013. ISBN: 978 92 4 150548 2. WHO reference number: WHO/HTM/TB/2013.6.

World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis Interim policy guidance. 10 June 2014. WHO reference number: WHO/HTM/TB/2014.23.

US Food and Drug Administration. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs [media release]. Aug 14 2019. Available from: [cited 7 February 2021]

Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 2020; 382: 893–902. doi: 10.1056/NEJMoa1901814

Cegielski JP. Tuberculosis multidrogo resistente en la era final de la tuberculosis. Rev Peru Med Exp Salud Publica 2018; 35(1): 110–7. doi: 10.17843/rpmesp.2018.351.3618

Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance surveillance. Global surveillance for antituberculosis-drug resistance, 1994–1997. N Engl J Med 1998 Jun 4; 338(23): 1641–9. doi: 10.1056/NEJM199806043382301

Laszlo A, Rahman M, Espinal M, Raviglione M; WHO/IUATLD Network of Supranational Reference Laboratories. Quality assurance program for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994–1998. Int J Tuberc Lung Dis 2002 Sep; 6(9): 748–56.

Zignol M, Dean AS, Falzon D, van Gemert W, Wright A, van Deun A, et al. Twenty years of global surveillance of antituberculosis-drug resistance. N Engl J Med 2016 Sep 15; 375(11): 1081–9. doi: 10.1056/NEJMsr1512438

World Health Organization Global Tuberculosis Database. Available from: [cited 1 July 2019].

The World Health Organization /International Union Against Tuberculosis and Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994 – 1997. Anti-tuberculosis drug resistance in the world. Geneva: WHO Global Tuberculosis Programme, Geneva; 1997, p. 14. WHO/TB/97.229.

Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: Department of Health and Human Services; 2013.

O’Neill, et al. Infection prevention, control and surveillance: limiting the development and spread of drug resistance. The review on antimicrobial resistance. World Bank; March 2016. Drug-resistant infections a threat to our economic future.

Nasreen S, Shokoohi M, Malvankar-Mehta MS. Prevalence of latent tuberculosis among health care workers in high burden countries: a systematic review and meta-analysis. PLoS One 2016; 11(10): e0164034. doi: 10.1371/journal.pone.0164034

Iseman MD. A clinician’s guide to tuberculosis. Philadelphia, PA: Lippincott Williams & Wilkins; 2000, pp. 115–28.

Tellier R, Li Y, Cowling BJ, Tang JW. Recognition of aerosol transmission of infectious agents: a commentary. BMC Infect Dis 2019; 19: 101, 1–9.

Nelson KE, Williams CM, eds. Infectious disease epidemiology: theory and practice – 3rd ed. Burlington, MA: Jones & Bartlett; 2014, pp. 465–610.

Masur H, Emanuel E, Lane HC. Severe acute respiratory syndrome: providing care in the face of uncertainty. JAMA 2003; 289: 2861–3. doi: 10.1001/jama.289.21.JED30036

Centers for Disease Control and Prevention. Update: outbreak of severe acute respiratory syndrome – worldwide, 2003. MMWR 2003; 52(12): 241–8.

International Labour Organization. Meeting of experts on updating the list of occupational diseases: report. Geneva, International Labour Organization; 13–20 December 2005, MEULOD/2005/10. Available from: [cited 25 February 2020].

Transatlantic Taskforce on Antimicrobial Resistance (TATFAR). TATFAR progress report May, 2014.

World Health Organization. WHO guidelines on tuberculosis infection prevention and control, 2019 update. Geneva: World Health Organization; 2019. License: CC BY-NC-SA 3.0 IGO.

Scott C, Mangan J, Tillova Z, Jensen PA, Ahmedov S, Ismoilova J, et al. Evaluation of the Tuberculosis Infection Control Training Center, Tajikistan, 2014–2015. Int J Tuberc Lung Dis 2017 May 1; 21(5): 579–85. doi: 10.5588/ijtld.16.0518

Cirule A. Oral presentation. Available from: [cited 1 July 2019].

Volchenkov G. Oral presentation: the global crisis of drug-resistant TB and leadership of BRICS countries: challenges and opportunities. Available from: [cited 1 July 2019].

Dokubo EK, Odume B, Lipke V, Mulanga C, Onu E. Olutola A, et al. MMWR – building and strengthening infection control strategies to prevent tuberculosis – Nigeria, 2015. Weekly 2016; 65(10): 263–6. doi: 10.15585/mmwr.mm6510a3

Ayalew A, Gashu Z, Anteneh T, Hiruy N, Habte D, Jerene D, et al. Improvement in tuberculosis infection control practice via technical support in two regions of Ethiopia. BMC Infect Dis 2018; 18: 557. doi: 10.1186/s12879-018-3459-0

Mphahlele MT, Tudor C, Van der Walt M, Farley J. An infection control audit in 10 primary health-care facilities in the Western Cape Province of South Africa. Int J Infect Control 2012; 8(3). doi: 10.3396/ijic.v8i3.025.12

Engelbrecht MC, Kigozi G, van Rensburg APJ, van Rensburg DHCJ. Tuberculosis infection control practices in a high-burden metro in South Africa: a perpetual bane for efficient primary health care service delivery. 2018 May 30.

Farley JE, Tudor C, Mphahlele M, Franz K, Perrin NA, Dorman S, et al. A national infection control evaluation of drug-resistant tuberculosis hospitals in South Africa. Int J Tuberc Lung Dis 2012 Jan; 16(1): 82–9. doi: 10.5588/ijtld.10.0791

Hospital Infections Program, National Center for Infectious Diseases, CDC. Public health focus: surveillance, prevention, and control of nosocomial infections. MMWR Weekly 1992; 41(42): 783–7.

Dixon RE. Control of health-care–associated infections, 1961–2011. MMWR 2011; 60: 58–63.

Castro KG, Marks SM, Chen MP, Hill AN, Becerra JE, Miramontes R, et al. Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades. Int J Tuberc Lung Dis 2016 July; 20(7): 926–33. doi: 10.5588/ijtld.15.1001

End TB Transmission Initiative. TB infection control in national TB program reviews. Geneva: Stop TB Partnership; 2018.

Chai SJ, Mattingly DC, Varma JK. Protecting health care workers from tuberculosis in China: a review of policy and practice in China and the United States. Health Policy Plan 2012. doi: 10.1093/heapol/czs029

Tudor C, Van der Walt M, Hill MN, Farley JE. Occupational health policies and practices related to tuberculosis in health care workers in KwaZulu-Natal, South Africa. Public Health Action 2013; 3(2): 141–5. doi: 10.5588/pha.12.0098

Castro JL. The World Health Organization made a big mistake on TB. It must fix it. Stat News, March 13, 2017. Available from: [cited 21 May 2019].

Ditiu L, Spigelman M, Castro JL. A baffling omission from the ‘priority pathogen’ list. Financial Times, March 5, 2017.

Stop TB Partnership. Open Letter to the WHO to put #TbontheList. TB Community Demands WHO to include #TbontheList! Available from: [cited 7 February 2021]

Green Light Committee. Instructions for applying to the Green Light Committee for access to second line anti-TB drugs, 2nd ed. Geneva: World Health Organization; 2006. WHO/HTM/TB/2006.369.

U.S. Congress, Office of Technology Assessment. Impacts of antibiotic-resistant bacteria, OTA-H-629. Washington, DC: U.S. Government Printing Office; September 1995.

Rosenkrantz BG. Coverage of antibiotic resistance in the popular literature, 1950 to 1994. Historical review: responses to antibiotic resistance. Contract Report to the Office of Technology Assessment; 1995.

The White House. National Action Plan for combating antibiotic-resistant bacteria. March 2015.

Hubel DH, Wiesel TN. Brain mechanisms of vision. Sci Am 1979 Sep; 241(3): 150–62. doi: 10.1038/scientificamerican0979-150

Vlaev I, King D, Dolan P, Darzi A. Theory and practice of ‘nudging’: changing health behaviors. Public Admin Rev 1979 July/August; 76(4): 550–561. doi: 10.1111/puar.12564

Dyson J, Lawton R, Jackson C, Cheater F. Development of a theory-based instrument to identify barriers and levers to best hand hygiene practice among health care practitioners. Implement Sci 2013; 8: 111. doi: 10.1186/1748-5908-8-111

How to Cite
Cegielski, J., Tudor, C., Volchenkov, G., & Jensen, P. (2021). Antimicrobial drug resistance and infection prevention/control: lessons from tuberculosis. International Journal of Infection Control, 17(1).